TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incidence of DLTs (Dose Escalation only)
Endpoint domain: Adverse events/effects
Primary endpoint: Local tolerability of the vaginal suppository ELTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QoR15 survey scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: clinico-radio-proteo-metabolic profile indicative of choroid plexus dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid difficulty Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Days alive outside hospital
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of patients hospitalized due to PN
Endpoint domain: Adverse events/effects
Primary endpoint: mHealth Satisfaction Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Emotion regulation skills use score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adipocytokines profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cervical cancer detection accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Risk of developing post-traumatic stress disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Handgrip strength using hand-held dynamometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Controlled Oral Word Association Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total amount of postoperative analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in WHO-5 Well-being Index at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hand movements-count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand movements-duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active joint range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrist distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Falling
Endpoint domain: Adverse events/effects
Primary endpoint: rate of postoperative bile leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Osteocalcin levels in gingival crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Number of Classes Attended
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Veterans Who Attend Majority of Classes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Changes in immunogenicity against Omicron BA.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of solicited local and systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Interleukin 6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of Tumoral Necrosis Factor-alpha (TNF-alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of C Reactive Protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biopsychosocial Response Scale of Nursing Students
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Long-term alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in peripheral arterial pressure (PAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cross-sectional area of the ulnar artery (SU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak systolic velocity of the ulnar artery (PSVU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Graft success or failure
Endpoint domain: Mortality/survival
Primary endpoint: Second opinion retention rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of drop-out/discontinuation of study intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Brain [ATP] as measured by 31P-Magnetic Resonance Spectroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrinogen/Albumin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-reactive protein/Albumin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Falls Efficacy Scale-International (FES-I)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tensomyography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of PDCM (patient derived cancer models)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of Whole Exome Sequencing (WES) e RNA-seq performed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence of PA sessions during pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived difficulty of PA sessions during pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Women's satisfaction of PA sessions during pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Left ventricular activation time (LVAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricular activation time (RVAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Paced QRS morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of severe and fatal clinical outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of lesions causing IDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in appetite- and satiety-related brain responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in gastric volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prediction of difficult intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure (diastolic and systolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perioperative major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Total Atheroma Volume (TAV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to normal frequency of stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area under the concentration versus time curve from 0 to infinity (AUC0-inf) of opevesostat in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of opevesostat in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal half-life (t1/2) of opevesostat in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving DAS28-CRP <= 3.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Subjects with no Heavy Drinking Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24-hour cough frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving ≥ 2mm Reduction in Proptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in metabolism as measured by maximum oxygen consumption (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in metabolism as measured by ventilation (VE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intervention acceptability by participants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intervention acceptability by program delivery staff
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lower Urinary Tract Symptoms Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Major congenital malformations
Endpoint domain: Mortality/survival
Primary endpoint: Fetal deaths/stillbirths
Endpoint domain: Mortality/survival
Primary endpoint: Small for gestational age births
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Participants with Cardiac Events of Any Toxicity Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Observed Concentration Immediately Prior to the Next Study Treatment Administration (Ctrough) of Daratumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of clinically relevant abnormalities in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Treatment-Related AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Nerve Conduction Velocity and Amplitude from Baseline on Nerve Conduction Studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Cellular and Humoral Response Against the Vector and Transgene in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NRS <3 at 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of protocol-specified adverse events (AEs) and their severity
Endpoint domain: Adverse events/effects
Primary endpoint: Rehospitalization for cardiovascular causes
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of noninvasive ventilation failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Baseline clinical characteristics of outpatients with uncontrolled asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of Treatment Response or Remission in Montgomery-Asberg Depression Rating Scale (MADRS) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of Duration of Remission of Depressive Symptoms in Montgomery-Asberg Depression Rating Scale (MADRS) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Operative Assessment Laparoscopic Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity of 18F-fluorofuranylnorprogesterone (FFNP) PET/MR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of 18F-fluorofuranylnorprogesterone (FFNP) PET/MR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (Tmax) of ABBV-1088
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in 24-hour urinary albumin to creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Endpoint domain: Adverse events/effects
Primary endpoint: Warwick-Edinburgh Mental Well-Being Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical success at 3, 6, and 12 months follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastroparesis Cardinal Symptom Index (GCSI) score before and after GPOEM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of salivary dosage of progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sit-and-Reach
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic Complete Response (pCR) Rate (Breast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pathologic Complete Response (pCR) Rate (Lymph Nodes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pathologic Complete Response (pCR) Rate (By Stage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Central aberration profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Peripheral aberration profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Improved control of chronic condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of resting-state functional connectivity (rsFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of mismatch negativity (MMN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Independence in using Rideshare
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Safety in using Rideshare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who experienced treatment-emergent adverse event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in SSB intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average score change in RDQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the concentration versus time curve from time 0 to last quantifiable sample (AUC0-last) of MK-8527 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of MK-8527 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal half-life (t1/2) of MK-8527 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with immunotherapy-related dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of AG-181
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve up to the Last Quantifiable Concentration (AUC0-last) of AG-181
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving SLE Responder Index (SRI)-4 Composite Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Integrated Alzheimer's Disease Rating Scale (iADRS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy of maxillary segment repositioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Joint Status at 36 Months based on HEAD-US Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical Joint Status at 36 Months based on HJHS v2.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Problem Joints at 36 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: AUC of vancomycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) leading to permanent dapirolizumab pegol discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants who have a CR + CRh + CRi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall response rate (CR + CR equivalent + PR + CRL + CRh + HI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of subjects with serum uric acid level ≤360 μmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-Reported ART Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Serum HIV RNA Quantitative Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HIV Medication Taking Self-Efficacy Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with Adverse events of special interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with >= 4 points reduction from Baseline in SELENA SLEDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of left atrial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Technical Procedure Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Sonazoid-enhanced ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Sonazoid-enhanced ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Sonazoid-enhanced ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients experiencing major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Plasma HIV-1 RNA ≥50 c/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient adherence to the diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Achievement of LDL-C targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number, Proportion, and Severity of Fever, Diarrhea, or Dysentery
Endpoint domain: Adverse events/effects
Primary endpoint: Number, Proportion, and Severity of Solicited Local and Systemic Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number, Proportion, Severity, and Relatedness of Non-Serious Unsolicited Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants experiencing solicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants experiencing medically attended adverse events (MAAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants experiencing unsolicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants experiencing new onset chronic medical conditions (NOCMCs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in total severity score of throat irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean number of migraine days per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of prescription of appropriate LDL-lowering therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinically significant lab abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Enrollment fraction of Black + Hispanic patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: EPC-CFU levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow Mediated Diameter Percentage (FMD%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Negative predictive value (NPV) for detection of sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Proportion of participants who have abstained from tobacco use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of contrast-enhanced mammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rigidity and bradykinesia assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcome (KOOS-JR)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Effectiveness of the ablation procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durability of the ablation procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Bradykinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any breastfeeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of total body weight loss (% TBWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with Post-COVID condition (PCC) up to 120 days after infection
Endpoint domain: Mortality/survival
Primary endpoint: Cutaneous temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes